About gt biopharma - GTBP
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.
GTBP At a Glance
GT Biopharma, Inc.
505 Montgomery Street
San Francisco, California 94111
| Phone | 1-415-919-4040 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -28,354,000.00 | |
| Sector | Health Technology | Employees | 1 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GTBP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.465 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.207 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
GTBP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -28,354,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GTBP Liquidity
| Current Ratio | 3.222 |
| Quick Ratio | 3.222 |
| Cash Ratio | 2.978 |
GTBP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -459.621 |
| Return on Equity | -1,377.411 |
| Return on Total Capital | -489.96 |
| Return on Invested Capital | -1,377.411 |
GTBP Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |